TABLE I.
Demographic and clinic-pathological characteristics of 82 prostate cancer patients in the current study
| Variables | No of patients (%) |
|---|---|
| Age at diagnosis | |
| Mean ± SD (yr) | 61.2 ± 6.3 |
| < median (60) | 35 (42.7) |
| ≥ median (60) | 47 (57.3) |
| Ethnicity | |
| Caucasian | 46 (56.1) |
| African-American | 10 (12.2) |
| Others | 26 (31.7) |
| Family history of prostate cancer | |
| No | 59 (72.0) |
| Yes | 20 (24.4) |
| Missing | 3 (3.6) |
| Prostate volume (ml) | |
| Mean ± SD | 53.0 (15.8) |
| < median (50) | 35 (42.7) |
| ≥ median (50) | 36 (43.9) |
| Missing | 11 (13.4) |
| PSA levels (ng/ml) | |
| Mean ± SD | 6.3 (6.0) |
| < 6 | 51 (62.2) |
| ≥ 6 | 24 (29.3) |
| Missing | 7 (8.5) |
| Tumor stage | |
| T2a | 5 (6.1) |
| T2b or T2c | 58 (70.7) |
| ≥ T3 | 19 (23.2) |
| Lymph node status | |
| Nx | 3 (3.7) |
| N0 | 78 (95.1) |
| N1 | 1 (1.2) |
| Metastasis status | |
| M0 | 82 (100.0) |
| Gleason sum score | |
| 6 | 24 (29.3) |
| 7 | 39 (47.5) |
| 8–9 | 19 (23.2) |
| Follow-up time | |
| Mean ± SD (months) | 18.3 ± 10.2 |
| < median (19.8) | 38 (46.3) |
| ≥ median (19.8) | 38 (46.3) |
| Missing | 6 (7.4) |
| Relapse status | |
| No | 71 (86.6) |
| Yes | 5 (6.1) |
| Missing | 6 (7.3) |
|
| |